Clinical Trial Phase I for Theragene in Combination With Chemotherapy for the Locally Advanced Pancreatic Cancer

Inclusion Criteria: * Patients with pancreatic cancer stage 3 * Patients with histologically confirmed pancreatic adenocarcinoma * Patients with no evidence of peritoneal or hematogenous metastasis * Patients with ECOG performance status 0-2 * Patients with renal function (Serum creatinine ≤ 1.5 mg/dL or creatinine clearance ≥ 50 mL/min/m²) * Patients with bone marrow function (WBC \> 4,000/uL or absolute neutrophil count ≥ 1500/uL, PLT ≥ 100,000/uL, and Hemoglobin \> 10 g/dL) * Patients with liver function (Bilirubin \< 2.0 mg/dL and SGOT and SGPT \< 2.5 times upper limit of normal (ULN)) * Patients with agreement with informed consent * Male patients with contraception Exclusion Criteria: * Female patients with childbearing age or pregnancy or breast feeding * Patients with a history of chemotherapy within 5 years * Patients with a history of radiation on more than 25% of bone marrow * Patients with unknown stage or recurrent pancreatic cancer * Patients with a history of skin cancer except malignant melanoma or malignancy except stage 0 cervical cancer * Patients with a history of major surgery except laparoscopic exam, endoscopic ultrasound, stenting, or PEG/PEJ placement * Patients with active or uncontrolled infection * Patients with immunosuppression or susceptibility to viral infection * Patients with HIV infection, chronic hepatitis B, chronic hepatitis C, or liver cirrhosis * Patients with a history of allergy to clinical trial medications * Patients who are considered as inappropriate candidate by investigators